Cable Hill Partners’s GSK GSK Stock Holding History

Cable Hill Partners’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$279K	Buy	+6,993	New	+$256K	0.03%	154
2023 Q1	–	Sell	-6,834	Closed	-$242K	–	211
2022 Q4	$242K	Buy	+6,834	New	+$228K	0.04%	169
2022 Q3	–	Sell	-5,710	Closed	-$311K	–	154
2022 Q2	$311K	Buy	+5,710	New	+$315K	0.08%	104
2019 Q2	–	Sell	-1,777	Closed	-$93K	–	356
2019 Q1	$93K	Sell	1,777 -72	-4%	-$3.6K	0.03%	180
2018 Q4	$88K	Buy	1,849 +1,680	+994%	+$82.7K	0.04%	174
2018 Q3	$8K	Hold	169	–	–	﹤0.01%	469
2018 Q2	$9K	Hold	169	–	–	﹤0.01%	497
2018 Q1	$8K	Hold	169	–	–	﹤0.01%	536
2017 Q4	$8K	Sell	169 -4,245	-96%	-$196K	﹤0.01%	623
2017 Q3	$224K	Buy	4,414 +4,334	+5,418%	+$220K	0.1%	83
2017 Q2	$4K	Hold	80	–	–	﹤0.01%	594
2017 Q1	$4K	Hold	80	–	–	﹤0.01%	576
2016 Q4	$4K	Sell	80 -325	-80%	-$16.1K	﹤0.01%	581
2016 Q3	$22K	Buy	+405	New	+$22.2K	0.02%	268
2015 Q2	–	Sell	-108	Closed	-$6K	–	737
2015 Q1	$6K	Hold	108	–	–	﹤0.01%	528
2014 Q4	$6K	Buy	+108	New	+$6.04K	0.01%	516

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cable Hill Partners's GSK Position: Q1 2025 in Review

Cable Hill Partners opened a new position in GSK (GSK) in Q1 2025: 6,993 shares worth $279K. The stake represents 0.03% of the portfolio and ranks #154 among its holdings. This is a return to the name: Cable Hill Partners previously reported a position in GSK as recently as Q4 2022.

Cable Hill Partners first reported a position in GSK in Q4 2014 and has held it in 16 quarters since. The position peaked at $311K in Q2 2022. 858 funds tracked by Wall St. Rank hold GSK as of Q1 2025.

Cable Hill Partners held 6,993 shares of GSK worth $279K as of Q1 2025.
GSK was a new Cable Hill Partners position in Q1 2025.
GSK made up 0.03% of Cable Hill Partners's portfolio in Q1 2025, its #154 holding.
Cable Hill Partners first reported a position in GSK in Q4 2014 and has held it in 16 quarters since.
Cable Hill Partners's GSK position peaked at $311K in Q2 2022.
858 funds tracked by Wall St. Rank held GSK as of Q1 2025.

Based on Cable Hill Partners's 13F filing for Q1 2025, filed 2 May 2025.